PMC Articles for PubChem Compound (Select 6450551) - PMC

Result Filters

Links from PubChem Compound

Items: 1 to 20 of 271

<< First< Prev

Page of 14

Select item 113009161.

The in vitro dynamics of pseudo-vascular network formation

Mariam-Eleni Oraiopoulou, Dominique-Laurent Couturier, Ellie V. Bunce, Ian G. Cannell, Paul W. Sweeney, Huw Naylor, Monika Golinska, Gregory J. Hannon, Vangelis Sakkalis, Sarah E. Bohndiek

Br J Cancer. 2024 Aug 24; 131(3): 457–467. Published online 2024 Jun 20. doi: 10.1038/s41416-024-02722-7

PMCID:: PMC11300916

Abstract Article PDF–3.1M

Select item 112786622.

Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study

Deniz Işık, Oğuzcan Kınıkoğlu, Goncagül Akdağ, Yunus Emre Altıntaş, Ezgi Türkoğlu, Sedat Yildirim, Heves Sürmeli, Tuğba Başoğlu, Hatice Odabaş, Nedim Turan

Medicina (Kaunas) 2024 Jul; 60(7): 1088. Published online 2024 Jul 2. doi: 10.3390/medicina60071088

PMCID:: PMC11278662

Abstract Article PDF–597K

Select item 112732323.

Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma

Neil J. Shah, Reshma Shinde, Kristin J. Moore, Amy Sainski-Nguyen, Lisa B. Le, Feng Cao, Rui Song, Puneet Singhal, Robert J. Motzer

JAMA Netw Open. 2024 Jul; 7(7): e2422674. Published online 2024 Jul 25. doi: 10.1001/jamanetworkopen.2024.22674

PMCID:: PMC11273232

Abstract Article

Select item 112660554.

Exploring the multifaceted antitumor activity of axitinib in lung carcinoids

Monica Oldani, Maria Celeste Cantone, Germano Gaudenzi, Silvia Carra, Alessandra Dicitore, Davide Saronni, Maria Orietta Borghi, Angela Lombardi, Michele Caraglia, Luca Persani, Giovanni Vitale

Front Endocrinol (Lausanne) 2024; 15: 1433707. Published online 2024 Jul 10. doi: 10.3389/fendo.2024.1433707

PMCID:: PMC11266055

Abstract Article PDF–4.7M

Select item 111681355.

Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial

Jiwei Huang, Yueming Wang, Fan Xu, Zaoyu Wang, Guangyu Wu, Wen Kong, NG Cheoklong, Thibault Tricard, Xiaorong Wu, Wei Zhai, Wei Zhang, Jiyang Zhang, Ding Zhang, Shuyin Chen, Yuqing Lian, Yonghui Chen, Jin Zhang, Yiran Huang, Wei Xue

J Immunother Cancer. 2024; 12(6): e008475. Published online 2024 Jun 11. doi: 10.1136/jitc-2023-008475

PMCID:: PMC11168135

Abstract Article PDF–1.1M

Select item 111582306.

Effect of axitinib (AG‐013736) on fatigue, thyroid‐stimulating hormone, and biomarkers: A phase I study in Japanese patients

Toru Mukohara, Hikaru Nakajima, Hirofumi Mukai, Shunji Nagai, Kuniaki Itoh, Yoshiko Umeyama, Junichi Hashimoto, Hironobu Minami

Cancer Sci. 2010 Apr; 101(4): 963–968. Published online 2009 Dec 9. doi: 10.1111/j.1349-7006.2009.01465.x

PMCID:: PMC11158230

Abstract Article PDF–540K

Select item 111498857.

Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects

Sophie J. Bakri, Jeff Lynch, Michelle Howard-Sparks, Stephan Saint-Juste, Said Saim

PLoS One. 2024; 19(6): e0304782. Published online 2024 Jun 4. doi: 10.1371/journal.pone.0304782

PMCID:: PMC11149885

Abstract Article PDF–2.9M

Select item 111028818.

Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib

Zhiyuan Lin, Shuxiu Xiao, Yu Qi, Jianming Guo, Lili Lu

J Cancer Res Clin Oncol. 2024; 150(5): 262. Published online 2024 May 19. doi: 10.1007/s00432-024-05803-5

PMCID:: PMC11102881

Abstract Article PDF–2.8M

Select item 110297969.

Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion

Stephanie Du Four, Sarah K. Maenhout, Daphné Benteyn, Brenda De Keersmaecker, Johnny Duerinck, Kris Thielemans, Bart Neyns, Joeri L. Aerts

Cancer Immunol Immunother. 2016 Jun; 65(6): 727–740. Published online 2016 Apr 20. doi: 10.1007/s00262-016-1836-3

PMCID:: PMC11029796

Abstract Article PDF–1.3M

Select item 1102809910.

The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models

Heinz Läubli, Philipp Müller, Lucia D’Amico, Mélanie Buchi, Abhishek S. Kashyap, Alfred Zippelius

Cancer Immunol Immunother. 2018 May; 67(5): 815–824. Published online 2018 Feb 27. doi: 10.1007/s00262-018-2136-x

PMCID:: PMC11028099

Abstract Article PDF–2.6M

Select item 1099163311.

Kan Liu, Yan Huang, Yu Xu, Guoqiang Wang, Shangli Cai, Xu Zhang, Taoping Shi

Cancer Immunol Immunother. 2023 Aug; 72(8): 2557–2572. Published online 2023 Apr 12. doi: 10.1007/s00262-023-03424-4

PMCID:: PMC10991633

Abstract Article PDF–5.6M

Select item 1099144912.

First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis

Yu Fujiwara, Hirotaka Miyashita, Bobby C. Liaw

Cancer Immunol Immunother. 2023 Jun; 72(6): 1355–1364. Published online 2022 Dec 10. doi: 10.1007/s00262-022-03341-y

PMCID:: PMC10991449

Abstract Article PDF–1.1M

Select item 1097755913.

Multiorgan failure caused by pembrolizumab and axitinib in a woman affected by metastatic clear cell renal cell carcinoma: A case report and literature review

Andrea Di Marco, Grazia Artioli, Adolfo Favaretto, Nicolò Cavasin, Umberto Basso

Medicine (Baltimore) 2024 Mar 29; 103(13): e37606. Published online 2024 Mar 29. doi: 10.1097/MD.0000000000037606

PMCID:: PMC10977559

Abstract Article PDF–429K

Select item 1092077014.

Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis

Xianhua She, Donghong Yin, Qian Guo, Yang Tang, Shuyun Wang, Xuyan Wang

Sci Rep. 2024; 14: 5592. Published online 2024 Mar 7. doi: 10.1038/s41598-024-56335-4

PMCID:: PMC10920770

Abstract Article PDF–2.9M

Select item 1090567115.

Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma

Toni K. Choueiri, Amber C. Donahue, David A. Braun, Brian I. Rini, Thomas Powles, John B.A.G. Haanen, James Larkin, Xinmeng Jasmine Mu, Jie Pu, Rosemary E. Teresi, Alessandra di Pietro, Paul B. Robbins, Robert J. Motzer

Cancer Discov. 2024 Mar 1; 14(3): 406–423. Published online 2023 Dec 21. doi: 10.1158/2159-8290.CD-23-0680

PMCID:: PMC10905671

Abstract Article PDF–9.5M

Select item 1085768616.

Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma

Kazuyuki Numakura, Ryoma Igarashi, Makoto Takahashi, Taketoshi Nara, Sohei Kanda, Mitsuru Saito, Shintaro Narita, Takamitsu Inoue, Takenori Niioka, Masatomo Miura, Tomonori Habuchi

Cancer Biol Ther. 2024; 25(1): 2312602. Published online 2024 Feb 7. doi: 10.1080/15384047.2024.2312602

PMCID:: PMC10857686

Abstract Article PDF–356K

Select item 1083917317.

In vitro evaluation of the antitumor activity of axitinib in canine mammary gland tumor cell lines

Hye-Gyu Lee, Ga-Hyun Lim, Ju-Hyun An, Su-Min Park, Kyoung-Won Seo, Hwa-Young Youn

J Vet Sci. 2024 Jan; 25(1): e1. Published online 2023 Nov 28. doi: 10.4142/jvs.23191

PMCID:: PMC10839173

Abstract Article PDF–5.6M

Select item 1078802618.

Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer

Jianfeng Zheng, Shan Jiang, Xuefen Lin, Huihui Wang, Li Liu, Xintong Cai, Yang Sun

BMC Womens Health. 2024; 24: 37. Published online 2024 Jan 13. doi: 10.1186/s12905-023-02864-5

PMCID:: PMC10788026

Abstract Article PDF–4.5M

Select item 1077490419.

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

Y. Tomita, R.J. Motzer, T.K. Choueiri, B.I. Rini, H. Miyake, M. Oya, L. Albiges, M. Aizawa, Y. Umeyama, J. Wang, A. di Pietro, M. Schmidinger

ESMO Open. 2023 Dec; 8(6): 102034. Published online 2023 Oct 20. doi: 10.1016/j.esmoop.2023.102034

PMCID:: PMC10774904

Abstract Article PDF–850K

Select item 1069009520.

PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

Michael E. Stokes, Veronica Calvo, Sho Fujisawa, Crissy Dudgeon, Sharon Huang, Nupur Ballal, Leyi Shen, Jennifer Gasparek, Matthew Betzenhauser, Simon J. Taylor, Kirk A. Staschke, Alan C. Rigby, Mark J. Mulvihill, Nandita Bose, Eric S. Lightcap, David Surguladze

Clin Cancer Res. 2023 Dec 1; 29(23): 4870–4882. Published online 2023 Sep 21. doi: 10.1158/1078-0432.CCR-23-1182

PMCID:: PMC10690095

Abstract Article PDF–5.2M

<< First< Prev

Page of 14

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

Find related data

Recent activity

Clear Turn Off Turn On

PMC Articles for PubChem Compound (Select 6450551) (271)
PMC
PREDICTED: homeobox-leucine zipper protein ATHB-15 isoform X1 [Tarenaya hassleri...
PREDICTED: homeobox-leucine zipper protein ATHB-15 isoform X1 [Tarenaya hassleriana]
gi|729357759|ref|XP_010545672.1|

Protein
PREDICTED: Homo sapiens histone deacetylase 2 (HDAC2), transcript variant X1, mR...
PREDICTED: Homo sapiens histone deacetylase 2 (HDAC2), transcript variant X1, mRNA
gi|2217361202|ref|XM_047418692.1|

Nucleotide
Taxonomy Links for Nucleotide (Select 2217361202) (1)
Taxonomy
PubChem Substance Links for Gene (Select 445347) (53)
PubChem Substance

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to: